The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study
Transplant Immunology · 2026-06 · 96 · 102385
DOI: 10.1016/j.trim.2026.102385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2026-06. Verfasst von Hanyu Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery/Gastrointestinal Surgery, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, Chi…. Hauptthemen laut MEDLINE: Graft Rejection, Sodium-Glucose Transporter 2 Inhibitors, Organ Transplantation, Sodium-Glucose Transporter 2. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) yield additional cardiorenal benefits beyond glycemic control. Emerging evidence suggests that SGLT2i have potential benefits in organ transplantation, though causal relationships remain unclear. This study aimed to investigate the causal effect of SGLT2 inhibition on transplant rejection and failure (TRF) and the mediating role of immune cell profiles. METHODS A drug-targeted and mediation mendelian randomization (MR) study was conducted. Genetic instruments for SGLT2 inhibition were constructed using variants associated with SLC5A2 expression and HbA1c reduction. Data on 731 immune cell traits came from a Sardinian cohort (n = 3757), and TRF data were sourced from the FinnGen consortium (289 cases, 392134 controls). The causal effects of SGLT2 inhibition on TRF and immune cells were estimated, followed by a mediation analysis to identify immune mediators. RESULTS Genetically proxied SGLT2i was associated with a reduced risk of TRF (OR = 0.81 per 0.66% HbA1c reduction, 95% CI: 0.70-0.93, P = 0.003). SGLT2i have a significant impact on 66 immune cell traits, including increasing naive B cells and Tregs while decreasing effector memory T cells, CD8 + NK cells and specific myeloid activation markers. Among these, a higher level of CD25hi CD45RA- CD4+ non-Treg cells was associated with increased TRF risk, but the mediation analysis failed to reach statistical significance (mediation effect: 5.86%; 95% CI: -0.63% to 12.35%; P = 0.076). CONCLUSION This MR study offers genetic evidence supporting SGLT2 inhibition's protective effect against TRF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery/Gastrointestinal Surgery, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China.
- Department of Nephrology, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China.
- Department of General Surgery/Gastrointestinal Surgery, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China. Electronic address: bschenh@163.com.
- Department of General Surgery/Gastrointestinal Surgery, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, China. Electronic address: 271640125@qq.com.
Zitieren
APA
Xiao, H., Zeng, X., Pang, Q., Chen, H., & Lai, S. (2026). The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study. Transplant Immunology, 96, 102385. https://doi.org/10.1016/j.trim.2026.102385
Vancouver
Xiao H, Zeng X, Pang Q, Chen H, Lai S. The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study. Transplant Immunology. 2026;96:102385. doi:10.1016/j.trim.2026.102385
BibTeX
@article{Xiao2026,
author = {Xiao, Hanyu and Zeng, Xiang and Pang, Qidan and Chen, Hong and Lai, Suhe},
title = {The effect of SGLT2 inhibition on immune cells and transplant rejection/failure: A drug-targeted mendelian randomization study},
journal = {Transplant Immunology},
year = {2026},
volume = {96},
pages = {102385},
doi = {10.1016/j.trim.2026.102385}
}
EUVIMED